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High-throughput, non-invasive prenatal
testing for fetal rhesus D status in RhD-
negative women: a systematic review and
meta-analysis
Huiqin Yang1*, Alexis Llewellyn2, Ruth Walker2, Melissa Harden2, Pedro Saramago3, Susan Griffin3 and
Mark Simmonds2
Abstract
Background: High-throughput non-invasive prenatal testing (NIPT) for fetal Rhesus D (RhD) status could avoid
unnecessary treatment with anti-D immunoglobulin for RhD-negative women found to be carrying an RhD-negative
fetus. We aimed to assess the diagnostic accuracy of high-throughput NIPT for fetal RhD status in RhD-negative
women not known to be sensitized to the RhD antigen, by performing a systematic review and meta-analysis.
Methods: Prospective cohort studies of high-throughput NIPT used to determine fetal RhD status were included. The
eligible population were pregnant women who were RhD negative and not known to be sensitized to RhD antigen.
The index test was high-throughput, NIPT cell-free fetal DNA tests of maternal plasma used to determine fetal RhD
status. The reference standard considered was serologic cord blood testing at birth. Databases including MEDLINE,
EMBASE, and Science Citation Index were searched up to February 2016.
Two reviewers independently screened titles and abstracts and assessed full texts identified as potentially relevant. Risk
of bias was assessed using QUADAS-2. The bivariate and hierarchical summary receiver-operating characteristic
(HSROC) models were fitted to calculate summary estimates of sensitivity, specificity, false positive and false negative
rates, and the associated 95% confidence intervals (CIs).
Results: A total of 3921 references records were identified through electronic searches. Eight studies were included in
the systematic review. Six studies were judged to be at low risk of bias. The HSROC models demonstrated high
diagnostic performance of high-throughput NIPT testing for women tested at or after 11 weeks gestation. In the
primary analysis for diagnostic accuracy, women with an inconclusive test result were treated as having tested positive.
The false negative rate (incorrectly classed as RhD negative) was 0.34% (95% CI 0.15 to 0.76) and the false positive rate
(incorrectly classed as RhD positive) was 3.86% (95% CI 2.54 to 5.82). There was limited evidence for non-white women
and multiple pregnancies.
Conclusions: High-throughput NIPT is sufficiently accurate to detect fetal RhD status in RhD-negative women and
would considerably reduce unnecessary treatment with routine anti-D immunoglobulin. The applicability of these
findings to non-white women and women with multiple pregnancies is uncertain.
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Introduction
Pregnant women who have an RhD-negative blood type
may carry an RhD-positive fetus. The presence of fetal
RhD-positive cells in the maternal circulation can cause
a mother who is RhD negative to produce anti-D anti-
bodies against the RhD antigen. This immune response,
termed sensitisation, can happen at any time during the
pregnancy, but it is most common in the third trimester
and during childbirth [1].
The process of sensitisation itself has no adverse ef-
fects on the mother and does not usually affect the preg-
nancy during which it occurs. However, in a subsequent
pregnancy with an RhD-positive fetus in women who
have been sensitized to the RhD antigen, the woman’s
anti-D antibodies may cross the placenta resulting in
haemolytic disease of the fetus and newborn.
This can cause severe fetal anemia that leads to fetal
heart failure, fluid retention and swelling (hydrops),
hyperbilirubinaemia, kernicterus, and perinatal death [2].
Prophylaxis with anti-RhD immunoglobulin can sub-
stantially reduce the risk of sensitisation in RhD-negative
women and hence the prevalence of haemolytic disease
of the fetus and newborn [3]. The introduction of rou-
tine antenatal prophylaxis during the third trimester of
pregnancy has led to a reduction in sensitisation, result-
ing in a decrease in mortality associated with haemolytic
disease of the fetus and newborn from 46 in 100,000
births before 1969 to 1.6 in 100,000 births by 1991 [4].
Currently, the National Institute for Health and Clin-
ical Excellence (NICE) guideline on antenatal care rec-
ommends that women should be offered testing for
blood group and rhesus D status in early pregnancy [5].
In those identified as RhD negative and without pre-
formed antibodies, administration of anti-D immuno-
globulin is recommended both as prophylaxis and
following potential sensitizing events to prevent the sen-
sitisation from occurring. Routine antenatal prophylaxis
with anti-D immunoglobulin can be given as two doses
at weeks 28 and 34 of pregnancy or as a single dose be-
tween 28 and 30 weeks [5].
Non-invasive prenatal testing (NIPT) of fetal RhD status
uses a real-time quantitative polymerase chain reaction
(PCR) method to detect cell-free fetal DNA—small frag-
ments of extracellular DNA shed from the placenta circu-
lating freely in the maternal plasma. High-throughput
NIPT performs the test using an automated platform cap-
able of performing a large number of tests simultaneously,
and is therefore suitable for large-scale population screen-
ing of pregnant women. High-throughput NIPT for fetal
RhD status may enable anti-D immunoglobulin to be
withheld from RhD-negative women who are predicted to
be carrying an RhD-negative fetus. Pregnant women
found to be carrying an RhD-negative fetus could avoid
unnecessary treatment with anti-D immunoglobulin
(which is a human polyclonal plasma-derived product),
along with the potential risk associated with administra-
tion of blood products. In addition, these women may
not need the provision of anti-D immunoglobulin fol-
lowing potentially sensitizing events, and there may
no longer be a need for serologic cord testing at
birth. High-throughput NIPT is already used in this
way in some European countries [6, 7].
However, the diagnostic accuracy of high-throughput
NIPT for fetal Rhesus D status in RhD-negative women
not known to be sensitized to the RhD antigen is uncer-
tain. The National Institute of Health Research Health
Technology Assessment programme commissioned a sys-
tematic review and economic evaluation to assess the diag-
nostic accuracy and cost-effectiveness of high-throughput
NIPT for the detection of fetal Rhesus D status in
RhD-negative women. This systematic review formed part
of a larger report on high-throughput NIPT which also
considered broader issues in its clinical value and imple-
mentation and a full economic analysis [8]. This work was
used to inform the recent NICE guideline regarding the
recommendation of high-throughput NIPT for fetal
Rhesus D status [9].
Methods
The complete methodology of the original wider review
is reported elsewhere [8]. This section summarizes the
methodology of the diagnostic accuracy review.
Data sources and searches
We conducted a systematic review following the PRISMA
statement [10] and registered the review on PROSPERO.
The following databases were searched for relevant studies
from inception to November 2015: MEDLINE, MEDLINE
In-Process, CINAHL, Cochrane Central Register of Con-
trolled Trials (CENTRAL), Cochrane Database of System-
atic Reviews (CDSR), Database of Abstracts of Reviews of
Effects (DARE), EMBASE, Health Technology Assessment
(HTA) database, Maternity and Infant Care, PubMed, and
the Science Citation Index. In addition, the following re-
sources were searched for on-going, unpublished, or gray
literature: ClinicalTrials.gov, Conference Proceedings
Citation Index: Science, EU Clinical Trials Register,
PROSPERO, and the WHO International Clinical Trials
Registry Platform portal. An updated search was per-
formed in February 2016.
Both published and unpublished literature were identi-
fied from systematic searches of electronic sources,
consultation with experts in the field, and reference
checking of relevant systematic reviews and included
studies. Search strategies were developed by an informa-
tion specialist (MH). The search strategy can be found
in Additional file 1.
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Study selection
Prospective cohort studies of high-throughput NIPT
used to determine fetal RhD status were eligible for in-
clusion. We considered as high-throughput, any NIPT
tests which were conducted using an automated robotic
platform (including automated DNA extraction and
liquid handling) and were able to process large numbers
of samples rapidly for large-scale screening purposes.
Studies where this test was used for diagnosis (rather
than screening) of sensitized women were excluded.
The inclusion criteria for population, index test, refer-
ence standard, and outcomes are listed below:
 The eligible population were pregnant women who
were RhD negative and not known to be sensitized
to RhD antigen.
 The index test was high-throughput, NIPT cell-free
fetal DNA tests of maternal plasma used to
determine fetal RhD status.
 The reference standard considered was serologic
cord blood testing at birth.
 The eligible studies had to report diagnostic
accuracy data such as absolute numbers of true
positive, false positive, true negative, and false
negative test results.
Two researchers independently screened the titles and
abstracts of all reports identified by the search strategy,
and full-text papers were subsequently obtained for as-
sessment. Only reports published in English were sought.
There were no restrictions for publication date. Full-text
copies of all studies deemed to be potentially relevant
were obtained and two reviewers independently assessed
them for inclusion (HY, AL). Any disagreements were re-
solved by consensus or by a third reviewer (RW).
Data extraction
We selected the most recent or most complete report
in cases of multiple reports for a given study or when
we could not exclude the possibility of overlapping
populations. One reviewer independently extracted de-
tails from full-text studies including study design, par-
ticipants, index, comparator and reference standard
tests, and outcome data. The data extraction was
checked by another reviewer. Any disagreements were
resolved by consensus (between HY and AL) or with a
third reviewer (RW).
We extracted the number of true positives, true nega-
tives, false positives, and false negatives for each index
test evaluated in each study in order to construct 2 × 2
tables. If reported, we extracted data on the number of
undetermined or uninterpretable results. Study authors
were contacted if some data were unclear or missing.
Quality assessment
Risk of bias was assessed using a modified version of
the quality assessment of diagnostic accuracy studies
(QUADAS-2) checklist [11]. The QUADAS-2 tool con-
sists of four key domains: (1) patient selection, (2)
index test, (3) reference standard, and (4) flow of pa-
tients through the study and timing of the index test(s)
and reference standard. Each domain was assessed in
terms of the risk of bias. The first three domains were
also assessed for concerns regarding their applicability
in terms of whether (1) the participants and setting, (2)
the index test, its conduct or interpretation, and (3) the
target condition as defined by the reference standard
were applicable to the UK context. One reviewer (AL)
independently assessed the quality of all included stud-
ies in terms of risk of bias. The quality assessment was
checked by another reviewer (HY). Any disagreements
were resolved by consensus or by a third party (RW).
Data synthesis
For diagnostic accuracy outcomes, estimates of sensitiv-
ity, specificity, and false positive and false negative rates
were calculated and presented on forest plots and in
receiver-operating characteristic (ROC) space to assess
the heterogeneity in test accuracy within and between
studies. The hierarchical bivariate model [12] was fitted
to calculate summary estimates of sensitivity, specificity,
and false positive and false negative rates and the associ-
ated 95% confidence intervals (CIs). The hierarchical
summary ROC (HSROC) model [13] was fitted to pro-
duce summary ROC curves. Both models jointly model
sensitivity and specificity and account for the correlation
between them. Heterogeneity in sensitivity and specifi-
city was also assessed using the I2 statistic. All analyses
were performed using R software [14, 15]. Because NIPT
testing is highly accurate, we present the results in terms
of the false positive rate (FPR) (incorrectly testing posi-
tive and being offered unnecessary anti-D prophylaxis)
and false negative rate (FNR) (incorrectly testing nega-
tive; at risk of sensitisation as women do not receive
anti-D prophylaxis), rather than the conventional sensi-
tivity and specificity.
Some NIPT results are inconclusive and unable to pre-
dict the RhD status of the fetus. Current UK practice is
to treat such test results as if they predicted an
RhD-positive fetus, and this approach was used in the
primary analysis of diagnostic accuracy. Sensitivity ana-
lyses were conducted to explore the robustness of the
results by including and excluding such inconclusive test
results. A further sensitivity analysis included only UK
(Bristol)-based studies, as this review was intended to in-
form UK practice. Furthermore, as test accuracy may
vary according to the gestation age when NIPT is per-
formed, we investigated the impact of test timing by
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plotting diagnostic accuracy against time, and perform-
ing meta-regressions against test timing. No analysis for
small study effects or publication bias was performed be-
cause there were too few studies identified to justify this.
Results
The literature searches of bibliographic databases identi-
fied 3921 references. After initial screening of titles and
abstracts, 227 were considered to be potentially relevant
and were ordered for full paper screening. In total, eight
studies [6, 7, 16–19] were included in the diagnostic re-
view of high-throughput NIPT testing. Six studies re-
ported inconclusive results. Figure 1 shows a flow
diagram outlining the screening process with reasons for
exclusion of full-text papers.
Table 1 presents the summary information of charac-
teristics of the included diagnostic accuracy studies. All
the studies were prospective studies and conducted in
European countries. Four studies were conducted in
England [16–19], three of which were based at Bristol
[16–18]. The sample size of studies ranged from 282 to
18,383. Most studies recruited pregnant women with a
gestational age of 10 to 28 weeks. Most participants were
white, and most pregnancies were singleton. All studies
used maternal plasma as their sample source. A robotic
DNA extraction instrument was employed in all studies.
The studies used a number of robotic platforms includ-
ing MDx BioRobot, MagNa Pure 96, MagNA Pure LC,
and COBAS AmpliPrep. For PCR, all studies targeted at
least two exons (generally exons 5 and 7) and at least
two controls for RHD assay (RhD-positive DNA and
RhD-negative DNA) except for the study by Wikman et
al. [20] which targeted exon 4 only and used GAPDH
DNA as control. The reference standard used in all stud-
ies was cord blood serology, except for Akolekar et al.
[17] which did not describe its reference standard.
Where reported, rates of inconclusive results ranged
from 1.0% [20] to 14.3% [19].
Risk of bias
Table 2 presents a summary of the results for the risk of
bias assessment. The majority of included studies were
judged to be at low risk of bias, but two studies [7, 19]
were judged to be at high risk of bias. The study by
Akolekar et al. [19] reported that the targeted RhD-
negative women were selected from a database, but it
was unclear whether this selection was conducted on a
random basis. The study enrolled a large proportion of
Africans (19.3%) which may not be representative of the
general population of pregnant women in the UK. This
may have contributed to the larger than average propor-
tion of inconclusive results (14.3%). Characteristics of
the reference standard were also poorly reported in this
study. In the study by Thurik et al. [7], only 80% of par-
ticipants received a reference standard. The reasons why
cord blood serology was not conducted in a significant
proportion of the study population were not stated. This
study also reported that its prediction algorithm was
judged daily and modified as needed, which may have
introduced bias in the diagnostic accuracy estimates.
Fig. 1 Flow diagram: study selection process
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Table 1 Characteristics of the diagnostic accuracy studies
Study
(First author/year)
Location DNA
extraction
tool
Exons
targeted
Controls Reference
standard
Gestational
age at time
of NIPT
(median/range)
Sample
sizeα
Confirmed
RhD
positive
Confirmed
RhD
negative
Inconclusive
test
results (%)
Reasons for inconclusive
results (n of cases)
Akolekar
2011 [19]
UK (London) MDx BioRobot
(Qiagen)
5 and 7 RhD+,
RhD–,
RHDΨ +,
No DNA
“Serologically
at delivery”
12.4 (11–14) 586 410 176 84 (14.3) Maternal or fetal RHD variant and insufficient
maternal plasma for further analysis (NR)!
Banch Clausen
2014 [6]
Denmark QIAsymphony SP;
MagNA Pure LC;
MagNA Pure
Compact
Instrument
(Roche)
5 and
10, or 5
and 7,
or 7
and 10
RhD+,
RhD–£
Cord blood
serology~
25 (23–28) 12,668 7830 4838 274 (2.2) Maternal weak D (93); maternal silent RHD
variant (38); high level of maternal background
DNA (29); technical problems (19); maternal DVI
(14); weak PCR signal (13); suspected maternal
RHD positive (3); no reported cause (65)
Chitty
2014 [16]
UK (Bristol) MDx
BioRobot
(Qiagen)
5 and 7 RhD+, RhD–,
RHDΨ+,
No DNA
Cord blood
serology
19 (5–35) 4913 2890 2023 393 (8.0) NR
Finning
2008 [17]
UK (Bristol) MDx
BioRobot
(Qiagen)
5 and 7 RhD+, RhD–,
RHDΨ+,
No DNA
Cord blood
serology>
28 (8–38) 1869 1156 713 56 (3.0) Insufficient DNA (30); suspected maternal RHD
gene (25); failure to extract DNA from plasma (1)
Grande
2013 [25]
Spain COBAS AmpliPrep
(Roche)
5 and 7,
10$
RhD+, RhD– Cord blood
serology
24–26 282 186 96 NR NR
Soothill
2015 [18]
UK (Bristol) MDx BioRobot
(Qiagen)
5 and 7 RhD+, RhD–,
RHDΨ+,
No DNA
Cord blood
serology
15–17 (mostly) 499* 315 184 61 (12.2) NR
Thurik
2015 [7]
Netherlands MagNa Pure
96 (Roche)
5 and 7 RhD+, RhD– Cord blood
serology^
26 18383* 11,283 7100 NR NR
Wikman
2012 [20]
Sweden MagNA Pure
LC (Roche)
4 GAPDH Serology from
cord blood
or citrate
samples from
newborns+
8–40 3291# 2073 1218 32 (1.0) RHD variant (14); no second sample
(18, of which 13 were spontaneous
abortions and miscarriages)
αNumber of blood samples unless otherwise specified; * number of participants; # excludes pre-8 weeks gestation pregnancies; $ on 2nd DNA extraction, only to confirm RHD-negative results;
£ Multiple controls without template were also included using sterile H2O;
! 5 mothers with insufficient DNA were excluded from the analyses and not classed as inconclusive
NR: not reported; RhD+: RhD positive; RhD−: RhD negative; PCR: Polymerase chain reaction; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; ~ Region 1: ID-Card DiaClon ABD-Confirmation for
donors, (DiaMed GmbH 1785 Cressier FR Switzerland) with monoclonal anti-D (cell lines ESD-1M, 175–2) that detects most weak RhD types and partial DVI phenotype; Region 2: direct agglutination in
a gel matrix test with IgM monoclonal anti-D clone 175–2 (DiaMed); further tests in gel matrix test with in-house Dw1 anti-D for initial negative tests. For discrepancies, DNA extracted from the cord
blood and tested for RHD exon 10 and further analyzed by PCR-SSP using the RH-type kit (Biologische Analysensystem GmbH, Lich, Germany); Region 3: Direct agglutination with monoclonal antibody
Diagast anti-D IgM (ref. no. 71000) for RHD positive. For unexpectedly negative reactions, an additional IAT with anti-D IgG LOR17 was performed. IAT with anti-D IgG LOR17 was used for RHD
negative; Region 4: Serological testing of cord blood RBC was done by using Seraclone Anti-D (RH1) Blend; Ref 802032 (Biotest, Germany); Region 5: Serological testing of cord blood RBC with 2
complete anti-Ds (Medion Diagnostics, IgM anti-D[MS201] and Seraclone, [Rh1] 226) in saline. For reactions of less than 3+ for both reagents, further investigation for D expression by IAT with two IgG
anti-Ds. > No DNA extraction of cord blood samples. ^ Cord blood serology with WA-Diana system (DiaMed GmbH) using two monoclonal anti-D reagents, LHM 59/20 (LDM3) + 175–2 and ESD- 1M+
175–2. Maternal and fetal RHD variant genes were analyzed with an RHD-multiplex ligation-dependent probe amplification (MLPA) assay on genomic DNA. Mutation analysis and copy number
variation investigated via RHD MLPA. Discordant positive results due to maternal or fetal RHD variants were identified and excluded from the study. Samples with weak PCR signals were excluded.
The Kleihauer–Betke test and multiplex short tandem repeat (STR)-PCRs on 15 systems on leukocyte-derived DNA were used exclude errors around cord blood collection. + Blood typing using DiaClon
ABO/Rh for Newborns DVI+ gelcards
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NIPT as an automated procedure was deemed to be of
limited risk to human error, and multiple controls were
used for RHD assays in all except one study [20]. The
index test of NIPT was conducted independent of the
reference standard, and the results of one were consid-
ered unlikely to influence the results of the other; there-
fore, the risk of incorporation bias was considered low.
It appears that most studies prospectively recruited
consecutive samples from clinical practice. Only three
studies stated that their diagnostic threshold was
pre-specified during the conduct of the screening pro-
gram [6, 16, 17].
The results of the studies were considered broadly
applicable to the use of high-throughput NIPT for
nationwide screening purposes, except for two studies
[19, 20]. In particular, the NIPT test used in the study by
Wikman et al. [21] only targeted exon 4, unlike all other
included studies where at least two exons (5, 7, and/or
10) were targeted. It is generally accepted that a combin-
ation such as of exons 5 and 7 should be targeted to
discriminate the pseudogene RHDΨ, particularly present
in individuals of African origin [22].
Meta-analysis
The results of the bivariate meta-analyses are shown in
Table 3. These show that NIPT is a highly accurate test.
The false negative rate (where women would not be
offered anti-D prophylaxis and so be at risk of sensitisa-
tion) is very low at 0.34% (95% CI 0.15 to 0.76). When
treating women with an inconclusive test result as if they
were positive, the false positive rate is 3.86% (95% CI 2.54
to 5.82). Excluding inconclusive test results reduces this to
1.26% (95% CI 0.87 to 1.83). Therefore, most false positive
results occur in women with inconclusive test results.
There was some evidence of inconsistency across stud-
ies. I2 was 75% for the false negative rate and 99% for
the false positive rate. It should be noted that these high
heterogeneities are, in part, a consequence of the high
accuracy of the test and the large size of the studies (and
consequent small within-study variance, because I2
increases as the average within-study variance declines).
They do not necessarily indicate any clinically meaning-
ful differences between studies. The heterogeneity in
false positive rates is likely to be a consequence of differ-
ing reporting and handling of inconclusive tests.
Studies conducted in Bristol had a lower false negative
rate (0.21%, 95% CI 0.09 to 0.48), with a consequently
higher false positive rate (5.73%, 95% CI 4.58 to 7.16). This
suggests that the Bristol high-throughput NIPT testing
approach, in which the MDx Bio Robot machine is used,
may be using a different test threshold to other countries,
which further minimizes false negative findings.
Figure 2 shows the results of the bivariate and the sum-
mary HSROC curve for this primary analysis, which is
presented in terms of false positive and false negative
rates. The black circle is the summary effect estimate from
a bivariate model, and the black curve is the HSROC
curve. This plot shows that the studies were generally con-
sistent in terms of false negative results, except for two
outlying studies [19, 20]. The study by Wikman et al. [20]
conducted most NIPT tests in the first trimester, earlier
Table 2 Risk of bias of included studies
Study Risk of bias Applicability concerns
Patient selection Index test Reference standard Flow and timing Patient selection Index test Reference standard
Akolekar (2011) [19] High High Unclear Unclear High Low Unclear
Banch-Clausen (2014) [6] Low Low Low Low Unclear Low Low
Chitty (2014) [16] Low Low Low Low Low Low Low
Finning (2008) [17] Low Low Low Low Low Low Low
Grande (2013) [25] Low Low Low Low Low Low Low
Soothill (2015) [18] Low Unclear Low Low Low Low Low
Thurik (2015) [7] Low High Low High Low Low Low
Wikman (2012) [20] Low Low Low Low Unclear High Low
High: high risk of bias; Low: low risk of bias
Table 3 Bivariate meta-analyses of false positive and negative rates
Analysis case Number of
studies
False negative rate (at risk of sensitisation) False positive rate (unnecessary anti-D)
Estimate (%) 95% CI Estimate (%) 95% CI
Inconclusive tests treated as test positive 8 0.34 0.15–0.76 3.86 2.54–5.82
Excluding all women with inconclusive test results 8 0.35 0.15–0.82 1.26 0.87–1.83
Studies conducted in Bristol only 3 0.21 0.09–0.48 5.73 4.58–7.16
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than other studies. The studies are less consistent in false
positive rates. This is most likely because the studies have
different numbers of inconclusive test results, and differ-
ent methods of handling such results.
Timing of NIPT tests
Figure 3 shows the false negative rates plotted by gesta-
tional age at time of high-throughput NIPT testing. It
suggests that false negative rates after the first trimester
(i.e., after around 13 weeks’ gestation) were consistent,
irrespective of timing, but false negative rates were
higher in the first trimester. This pattern is most visible
in the Chitty study [16] which reported diagnostic
accuracy at a range of test timings. Given the limited
amount of data, no formal statistical test could be per-
formed to confirm this conclusion. Additional file 2:
Figure S1 shows the false positive rates plotted by gesta-
tional age at time of high-throughput NIPT testing.
There was no obvious pattern from this figure.
We also evaluated the impact of the timing of
high-throughput NIPT testing on the number of
inconclusive test results. As seen in Additional file 3:
Figure S2, there is a suggestion that the percentage of
inconclusive results for this test reduces as the gesta-
tional age increases. This is most obvious in the study
by Chitty et al. [16].
Fig. 2 HSROC and bivariate meta-analysis
Fig. 3 False negative rate by gestational age at time of NIPT
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Impact on UK practice
We considered the likely impact of implementing NIPT
to guide anti-D prophylaxis in the UK by conducting a
simulation study, simulating a representation of the UK
population using data sourced from the review (see
Additional file 4 for input parameters).
Based on the results of the three Bristol-based studies,
we assumed that 60.7% of RhD-negative women have an
RhD-positive fetus, and 6.7% of women have an incon-
clusive NIPT result. Given this, the results of the diag-
nostic meta-analysis, and parameters described in
Additional file 4, using NIPT would result in anti-D
prophylaxis being received by 65.9% of RhD-negative
women. It would reduce the numbers of women receiv-
ing unnecessary anti-D from 38.9 to 5.7%. The number
of women who miss out on potentially beneficial anti-D
would rise from 0.6 to 1.2%, leading to potentially more
sensitisations: an extra 3 per 100,000 women if postpar-
tum cord blood testing continues, or 13 per 100,000 if it
is withdrawn. Sensitisation rates using universal anti-D
administration were estimated to be 280 per 100,000
women, so this increase is small.
It would however mean 0.12% of women with an
RhD-positive fetus would not be offered anti-D and so
would be at risk of sensitisation.
Discussion
In this systematic review, we identified eight studies that
evaluated diagnostic accuracy of high-throughput NIPT.
Six of these studies were judged to be at low risk of bias.
Meta-analyses showed very high diagnostic accuracy of
high-throughput NIPT testing.
Diagnostic accuracy of high-throughput NIPT varied
by gestational age. The data suggest that high-
throughput NIPT testing is insufficiently accurate in the
first trimester, but is consistently accurate at any time
thereafter. This might be due to low concentration of
cell-free fetal DNA in early pregnancy [23] but an in-
creased concentration of cell-free fetal DNA after the
end of the first trimester [24].
Given the very high diagnostic accuracy performance
of high-throughput NIPT testing, implementing high-
throughput NIPT for fetal RhD screening in all RhD-
negative women nationwide could be feasible. The
results suggest it would substantially reduce the need for
antenatal anti-D prophylaxis, while only marginally
increasing the risk of sensitisation due to false negative
test results. NIPT testing could be conducted, with low
false positive rates, at any time from the second trimes-
ter onwards, perhaps to coincide with routine antenatal
blood tests. Any nationwide NIPT screening program
will require careful logistical management to ensure that
blood samples are transported to laboratories and tested
quickly and that results are reliably returned to general
practitioners and midwives.
Limitations
We performed extensive literature searches with an
attempt to maximize retrieval of potentially relevant stud-
ies. These included electronic searches of a variety of
bibliographic databases as well as screening of clinical trial
registers and conference proceedings to identify unpub-
lished studies. However, only studies in English were
included; therefore, some potentially relevant non-English
language studies may have been missed. There was some
evidence of inconsistency in the meta-analysis of diagnos-
tic accuracy studies. The observed heterogeneity may be
due to variations in methods used in the high-throughput
NIPT approach (e.g., different diagnostic accuracy thresh-
olds used, and different number and types of exons
targeted, gestational age at the time of testing, and differ-
ent methods of handling inconclusive test results). In
addition, there was variation in the reporting of included
studies. Particularly, two studies [7, 25] did not report the
number of inconclusive results of the test and some stud-
ies did not report detailed reasons for inconclusive results.
The simulation study assumes that the input probabilities
are accurate and does not account for any uncertainty in
their estimation. Therefore, results of the simulation study
should be considered to be illustrative only and not defini-
tive estimates of effect.
Implications for future research
Further large prospective cohort studies evaluating diag-
nostic accuracy of high-throughput NIPT in women of
non-white ethnicity are required. This is of particular con-
cern as non-white women are more likely to have less
accurate test results. For example, in people with African
ethnicity, because of the presence of RHD pseudogene
[26], prenatal detection of fetal RhD type from maternal
blood would lead to higher rates of false positive results in
this particular population. Further research to improve
the NIPT test itself is also warranted, especially for redu-
cing the number of inconclusive test results.
Conclusions
The findings from this systematic review have demon-
strated high diagnostic performance of high-throughput
NIPT testing for the detection of fetal RhD status in
RhD-negative women, with very low false positive and false
negative rates in women tested at or after 11 weeks’ gesta-
tion. The use of high-throughput NIPT testing as a routine
screening test for fetal RhD status in RhD-negative women
can largely remove unnecessary exposure to prophylactic
anti-D treatment. Due to limited evidence, the accuracy of
NIPT in non-white women and multiple pregnancies is
unclear.
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